Atrasentan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 505 publications

Sibeprenlimab (Voyxact) for primary immunoglobulin A nephropathy.

Sibeprenlimab (Voyxact) for primary immunoglobulin A nephropathy.

Journal: The Medical letter on drugs and therapeutics

Published: July 24, 2026

Next-generation therapeutics and renaissance of legacy drugs targeting the endothelin system.

Next-generation therapeutics and renaissance of legacy drugs targeting the endothelin system.

Journal: Canadian journal of physiology and pharmacology

Published: June 30, 2026

Long-term kidney protection in IgA nephropathy with atrasentan.

Long-term kidney protection in IgA nephropathy with atrasentan.

Journal: Nature reviews. Nephrology

Published: June 24, 2026

Atrasentan: new molecule in the therapy of IgA nephropathy and other glomerulopathies.

Atrasentan: new molecule in the therapy of IgA nephropathy and other glomerulopathies.

Journal: Ceska a Slovenska farmacie : casopis Ceske farmaceuticke spolecnosti a Slovenske farmaceuticke spolecnosti

Published: June 23, 2026

New and Emerging Nonimmunosuppressive Drug Therapies for Primary Adult Glomerular Diseases.

New and Emerging Nonimmunosuppressive Drug Therapies for Primary Adult Glomerular Diseases.

Journal: Kidney medicine

Published: May 21, 2026

EDNRA Forms a Positive Feedback Loop with the Hippo/YAP Axis to Drive Triple-Negative Breast Cancer Progression.

EDNRA Forms a Positive Feedback Loop with the Hippo/YAP Axis to Drive Triple-Negative Breast Cancer Progression.

Journal: Advanced science (Weinheim, Baden-Wurttemberg, Germany)

Published: May 13, 2026

Endothelin Receptor Antagonists in Resistant Hypertension and Proteinuric Kidney Disease: Receptor Strategy and Volume Management.

Endothelin Receptor Antagonists in Resistant Hypertension and Proteinuric Kidney Disease: Receptor Strategy and Volume Management.

Journal: Journal of clinical hypertension (Greenwich, Conn.)

Published: May 05, 2026

Characterization of Atrasentan Metabolic Pathway in Human Liver Microsomes Using Feature-Based Molecular Networking.

Characterization of Atrasentan Metabolic Pathway in Human Liver Microsomes Using Feature-Based Molecular Networking.

Journal: Pharmaceutics

Published: May 04, 2026

Endothelial DNA Damage Orchestrates Cardio-Kidney-Metabolic Dysfunction Through Endothelin-1 Signaling.

Endothelial DNA Damage Orchestrates Cardio-Kidney-Metabolic Dysfunction Through Endothelin-1 Signaling.

Journal: Arteriosclerosis, thrombosis, and vascular biology

Published: April 30, 2026

Atrasentan in patients with IgA nephropathy (ALIGN): final 2·5-year results from a randomised, double-blind, placebo-controlled, phase 3 trial.

Atrasentan in patients with IgA nephropathy (ALIGN): final 2·5-year results from a randomised, double-blind, placebo-controlled, phase 3 trial.

Journal: Lancet (London, England)

Published: April 07, 2026

Improving the Cardiorenal Usability of Endothelin Receptor Antagonism in Albuminuric Chronic Kidney Disease: A Testable Role for SGLT2 Inhibitor-based Mitigation of Fluid Retention.

Improving the Cardiorenal Usability of Endothelin Receptor Antagonism in Albuminuric Chronic Kidney Disease: A Testable Role for SGLT2 Inhibitor-based Mitigation of Fluid Retention.

Journal: Cardiovascular drugs and therapy

Published: April 03, 2026

Progress in mechanistic and clinical translational research of endothelin A receptor antagonists in the treatment of diabetic kidney disease: a narrative review.

Progress in mechanistic and clinical translational research of endothelin A receptor antagonists in the treatment of diabetic kidney disease: a narrative review.

Journal: Frontiers in endocrinology

Published: February 10, 2026

Showing 1-12 of 505

Last Updated: 09/26/2026